12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lipotecan regulatory update

Taiwan Liposome said China's State Food and Drug Administration (SFDA) accepted Lipotecan into the Green Path program, an accelerated approval process under which the...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >